INS and type 2 diabetes mellitus: For people with T2DM, FSL has been found to be cost effective for those using basal insulin in Canada (FSL was dominant) [58], Italy (ICER, €10,556/QALY) [59], or the USA (FSL was dominant) [60]; the Canadian study also found FSL to be dominant to SMBG for people using non-insulin therapies or intensive insulin therapy [58].